The purpose of this study was to determine whether stimulant users are at higher risk of a later cardiovascular event than are non-users, examining this association in both a national cohort and a population-based sample of children and adolescents diagnosed with attention-deficit/hyperactivity disorder (ADHD). We also aim to examine a possible dose-response relationship in such an association.
Methods:
We conducted a longitudinal, prospective cohort study of all children born in Denmark between 1990 and 1999. Within this cohort, children with ADHD were identified. Data from national health registers on psychiatric and somatic diagnoses, stimulant prescriptions, cardiovascular risk factors, pre- and perinatal and sociodemographic covariates in all children and their parents were merged, using the unique personal identification number. Hazard ratios (HR) for cardiovascular events were estimated using Cox regression, adjusted for other known risk factors.
Results:
In the total population (n=714,258 contributing a total of 6,767,982 person-years) use of stimulants increased the risk of a cardiovascular event; adjusted HR=1.83 (1.10–3.04). In children with ADHD (n=8300) stimulant treatment also increased the risk of a cardiovascular event (adjusted HR=2.20 [2.15–2.24]), with a complex time-dependent dose-response relationship.
Conclusions:
This is the first nationwide cohort study of the cardiovascular safety of stimulants in children and adolescents, and it represents, to our knowledge, the longest prospective follow-up study. Cardiovascular events were rare but twice as likely in stimulant users as in non-users, both in the total national population and in children with ADHD. We found a complex, time- and dose-dependent interrelationship between cardiovascular adverse events and stimulant treatment in children and adolescents. Our results suggest a safety signal with an increased risk of cardiovascular disease associated with stimulant treatment in children and adolescents, even after adjusting for a number of potential confounders.
Get full access to this article
View all access options for this article.
References
1.
AileruAA, CarpentierRG: Mechanisms of the in vitro effects of amphetamine on rat sinus node automaticity and membrane potentials of atrial fibers. J Electrocardiol, 29:123–130, 1996.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC; American Psychiatric Association, 2000.
3.
ArcieriR, GerminarioEAP, BonatiM, MasiG, ZuddasA, VellaS, ChiarottiF, Panei, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers: Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol, 22:423–431, 2012.
4.
BahceliogluM, GozilR, TakeG, ElmasC, OktemH, KadiogluD, CalgunerE, ErdoganD, SargonMF, YaziciAC, TasM, BardakciY, SenolS: Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat. World J Biol Psychiatry, 10:531–543, 2009.
5.
BuchhornR, ConzelmannA, WillaschekC, StorkD, TaurinesR, RennerTJ: Heart rate variability and methylphenidate in children with ADHD. Atten Defic Hyperact Disord, 4:85–91, 2012a.
6.
BuchhornR, MullerC, WillaschekC, NoroziK.: How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: Methylphenidate improves autonomic dysfunction in children with ADHD. ISRN Pharm, 2012:170935, 2012b.
7.
CasisO, EspiñaL, GallegoM: Effects of amphetamine on calcium and potassium currents in rat heart. J Cardiovasc Pharmacol, 36:390–395, 2000.
8.
CooperWO, HabelLA, SoxCM, ChanKA, ArbogastPG, CheethamTC, MurrayKT, QuinnVP, SteinCM, CallahanST, FiremanBH, FishFA, KirshnerHS, O'DuffyA, ConnellFA, RayWA: ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med, 365:1896–1904, 2011.
9.
DalsgaardS, LeckmanJF, NielsenHS, SimonsenM: Gender and injuries predict stimulant medication. J Child Adolesc Psychopharmacol., 2014 [Epub ahead of print].
10.
DalsgaardS, MortensenPB, FrydenbergM, ThomsenPH: Conduct problems, gender and adult psychiatric outcome of children with attention-deficit hyperactivity disorder. Br J Psychiatry, 181:416–421, 2002.
11.
DalsgaardS, NielsenHS, SimonsenM: Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: A Danish register-based study. J Child Adolesc Psychopharmacol, 23:432–439, 2013a.
12.
DalsgaardS, HumlumMK, NielsenHS, SimonsenM. Common Danish standards in prescribing medication for children and adolescents with ADHD. Eur Child Adolesc Psychiatry DOI: 10.1007/s00787-013-0508-5, 2013b.
13.
DreselS, KrauseJ, KrauseKH, LaFougereC, BrinkbaumerK, KungHF, HahnK, TatschK: Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med, 27:1518–1524, 2000.
14.
FindlingRL, ShortEJ, ManosMJ: Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry, 40:525–529, 2001.
15.
Fusar–PoliP, RubiaK, RossiG, SartoriG, BalottinU: Striatal dopamine transporter alterations in ADHD: Pathophysiology or adaptation to psychostimulants?. A meta-analysis. Am J Psychiatry, 169:264–272, 2012.
16.
GrahamJ, BanaschewskiT, BuitelaarJ, CoghillD, DanckaertsM, DittmannRW, DopfnerM, HamiltonR, HollisC, HoltmannM, Hulpke–WetteM, LecendreuxM, RosenthalE, RothenbergerA, SantoshP, SergeantJ, SimonoffE, Sonuga–BarkeE, WongIC, ZuddasA, SteinhausenHC, TaylorE: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry, 20:17–37, 2011.
17.
GrahamJ, CoghillD: Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs, 22:213–237, 2008.
18.
HabelLA, CooperWO, SoxCM, ChanKA, FiremanBH, ArbogastPG, CheethamTC, QuinnVP, DublinS, BoudreauDM, AndradeSE, PawloskiPA, RaebelMA, SmithDH, AchacosoN, UratsuC, GoAS, SidneyS, Nguyen–HuynhMN, RayWA, SelbyJV: ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA., 306:2673–2683, 2011.
19.
HamiltonRM, RosenthalE, Hulpke–WetteM, GrahamJG, SergeantJ: Cardiovascular considerations of attention deficit hyperactivity disorder medications: A report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young, 22:63–70, 2012.
20.
HendersonTA, FischerVW: Effects of methylphenidate (Ritalin) on mammalian myocardial ultrastructure. Am J Cardiovasc Pathol, 5:68–78, 1995.
21.
HolickCN, TurnbullBR, JonesME, ChaudhryS, BangsME, SeegerJD: Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol, 29:453–460, 2009.
22.
HuangYS, TsaiMH: Long-term outcomes with medications for attention-deficit hyperactivity disorder: Current status of knowledge. CNS Drugs, 25:539–554, 2011.
23.
ImerajL, AntropI, RoeyersH, DeschepperE, BalS, DeboutteD: Diurnal variations in arousal: a naturalistic heart rate study in children with ADHD. Eur Child Adolesc Psychiatry, 20:381–392, 2011.
24.
JiaoX, VelezS, RingstadJ, EymaV, MillerD, BleibergM: Myocardial infarction associated with adderall XR and alcohol use in a young man. J Am Board Fam Med, 22:197–201, 2009.
25.
KauppilaE, VanninenE, KuuselaT, KaurijokiS, KarhunenL, PietilainenKH, RissanenA, KaprioJ, TiihonenJ, KuikkaJ: Cardiac repolarization and striatal dopamine transporter function are interrelated. Nucl Med Commun, 30:713–717, 2009.
26.
KrauseKH, DreselSH, KrauseJ, KungHF, TatschK: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett, 285:107–110, 2000.
27.
KrautAA, LangnerI, LindemannC, BanaschewskiT, PetermannU, PetermannF, MikolajczykRT, GarbeE: Comorbidities in ADHD children treated with methylphenidate: a database study. BMC Psychiatry, 13:11, 2013.
28.
LangHC, SchefflerRM, HuTW: The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994–2003: A global pharmaceutical data analysis. Health Policy, 97:71–78, 2010.
29.
LinnetKM, DalsgaardS, ObelC, WisborgK, HenriksenTB, RodriguezA, KotimaaA, MoilanenI, ThomsenPH, OlsenJ, JarvelinMR: Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: Review of the current evidence. Am J Psychiatry, 160:1028–1040, 2003.
30.
LinnetKM, WisborgK, SecherNJ, Hove ThomsenP, ObelC, DalsgaardS, HenriksenTB: Coffee consumption during pregnancy and the risk of hyperkinetic disorder and ADHD: A prospective cohort study. Acta Paediatr, 98:173–179, 2009.
31.
Martinez–RagaJ, KnechtC, SzermanN, MartinezMI: Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs, 27:15–30, 2013.
32.
MickE, McManusDD, GoldbergRJ: Meta–analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol, 23:534–541, 2013.
33.
OlfsonM, HuangC, GerhardT, WintersteinAG, CrystalS, AllisonPD, MarcusSC: Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 51:147–156, 2012.
34.
PalomarAR, LariosBN, De SanchezVC, PerezLM, Lopez FdeL, FloresG, Gomez–Villalobos MdeJ: Expression and distribution of dopamine transporter in cardiac tissues of the guinea pig. Neurochem Res, 36:399–405, 2011.
35.
PedersenCB, GøtzscheH, MøllerJØ, MortensenPB: The Danish Civil Registration System – A cohort of eight million persons. Dan Med Bull, 53:441–449, 2006.
SamuelsJA, FrancoK, WanF, SorofJM: Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: A double-blind, randomized, cross-over trial. Pediatr Nephrol, 21:92–95, 2006.
38.
SAS Institute Inc.: SAS (release 9.2). Cary, NC: SAS Institute Inc.; 2000.
39.
SchellemanH, BilkerWB, KimmelSE, DanielGW, NewcombC, GuevaraJP, CzirakyMJ, StromBL, HennessyS: Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry, 169:178–185, 2012.
40.
SchellemanH, BilkerWB, StromBL, KimmelSE, NewcombC, GuevaraJP, DanielGW, CzirakyMJ, HennessyS: Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics, 127:1102–1110, 2011.
41.
SchimpfR, BorggrefeM, WolpertC. Clinical and molecular genetics of the short QT syndrome. Curr Opin Cardiol, 23:192–198, 2008.
42.
TsujiH, LarsonMG, VendittiFJJr., MandersES, EvansJC, FeldmanCL, LevyD: Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation, 94:2850–2855, 1996.
43.
VetterVL, EliaJ, EricksonC, BergerS, BlumN, UzarkK, WebbCL: Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation, 117:2407–2423, 2008.
44.
VitielloB, ElliottGR, SwansonJM, ArnoldLE, HechtmanL, AbikoffH, MolinaBS, WellsK, WigalT, JensenPS, GreenhillLL, KaltmanJR, SevereJB, OdbertC, HurK, GibbonsR: Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry, 169:167–177, 2012.
45.
WestoverAN, HalmEA: Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc Disord, 12:41, 2012.
46.
WintersteinAG, GerhardT, ShusterJ, JohnsonM, ZitoJM, SaidiA: Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 120:e1494–e1501, 2007.
47.
WintersteinAG, GerhardT, ShusterJ, SaidiA: Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics, 124:e75–80, 2009.
48.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
